Drugs / Recombinant human hyaluronidase PH20
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04484337 | Jul 2020 → May 2023 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 23 trials · 3 met primary | ||||||
| Phase 2 | NCT01194245 | Aug 2010 → Aug 2011 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | Met primary |
| Phase 2 | NCT01194258 | Aug 2010 → Aug 2011 | type 2 diabetes mellitus | Halozyme Therapeutics | Completed | Met primary |
| Phase 2 | NCT00774800 | Oct 2008 → Mar 2009 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | Met primary |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT01526733 | Dec 2011 → Aug 2012 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | Met primary |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01275131 Comparator | Jan → Dec 2011 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00916357 Comparator | Jul → Nov 2009 | type 2 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00883558 Background | May 2009 → Feb 2010 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | Met primary |
Press releases naming this drug 22 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human hyaluronidase PH20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00916357 ↗ |
| Known as | rHuPH20 | “Co-administration with recombinant human hyaluronidase (rHuPH20), topical nonsteroidal anti-inflammatory drug, or topical steroid was evaluated for some SC injections.” PMID 40296638 ↗ Apr 20251“Drug: Recombinant human hyaluronidase PH20 (rHuPH20)” NCT01275131 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human hyaluronidase PH20 (rHuPH20) is approved by the FDA for use as an aid in the absorption and dispersion of other injectable drugs.” NCT00774800 ↗ |
| Route | Subcutaneous | “100 U/mL non-preserved (NP) formulation of regular human insulin with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals” NCT00883558 ↗ |